Robbie Marcus
Stock Analyst at JP Morgan
(4.18)
# 397
Out of 4,784 analysts
157
Total ratings
57.69%
Success rate
10.75%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Overweight | $120 → $110 | $84.98 | +29.44% | 4 | Mar 7, 2025 | |
| RXST RxSight | Maintains: Overweight | $62 → $40 | $26.67 | +49.98% | 4 | Feb 26, 2025 | |
| BAX Baxter International | Maintains: Neutral | $38 → $36 | $33.70 | +6.82% | 17 | Feb 21, 2025 | |
| CNMD CONMED | Downgrades: Neutral | $85 → $70 | $59.85 | +16.96% | 6 | Feb 6, 2025 | |
| SYK Stryker | Maintains: Overweight | $420 → $445 | $367.54 | +21.08% | 9 | Jan 29, 2025 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $575 → $675 | $507.90 | +32.90% | 5 | Jan 24, 2025 | |
| NPCE NeuroPace | Maintains: Overweight | $9 → $14 | $12.38 | +13.09% | 4 | Dec 17, 2024 | |
| BVS Bioventus | Upgrades: Neutral | $12 → $13 | $9.09 | +43.01% | 3 | Dec 17, 2024 | |
| ZBH Zimmer Biomet Holdings | Upgrades: Overweight | $125 → $128 | $112.15 | +14.13% | 5 | Dec 17, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $100 → $110 | $100.80 | +9.13% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $260.26 | +26.80% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $19.83 | +61.37% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $34.37 | +16.38% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $78 | $71.19 | +9.57% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $69.43 | +22.43% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $81.66 | +10.21% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $38.88 | +28.60% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $5.84 | - | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $8.37 | -4.42% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $36 → $13 | $12.33 | +5.43% | 5 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $269.62 | -7.28% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $11.51 | +39.01% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $7.14 | -1.96% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $340 → $181 | $160.94 | +12.46% | 4 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $56 → $43 | $22.01 | +95.37% | 5 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $14.97 | +13.56% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $131.35 | -10.16% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $106.11 | +47.02% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $88.98 | +18.00% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $103.62 | -61.40% | 2 | May 5, 2020 |
The Cooper Companies
Mar 7, 2025
Maintains: Overweight
Price Target: $120 → $110
Current: $84.98
Upside: +29.44%
RxSight
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $40
Current: $26.67
Upside: +49.98%
Baxter International
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $33.70
Upside: +6.82%
CONMED
Feb 6, 2025
Downgrades: Neutral
Price Target: $85 → $70
Current: $59.85
Upside: +16.96%
Stryker
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $367.54
Upside: +21.08%
Intuitive Surgical
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $507.90
Upside: +32.90%
NeuroPace
Dec 17, 2024
Maintains: Overweight
Price Target: $9 → $14
Current: $12.38
Upside: +13.09%
Bioventus
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $9.09
Upside: +43.01%
Zimmer Biomet Holdings
Dec 17, 2024
Upgrades: Overweight
Price Target: $125 → $128
Current: $112.15
Upside: +14.13%
Boston Scientific
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $100.80
Upside: +9.13%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $260.26
Upside: +26.80%
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $19.83
Upside: +61.37%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $34.37
Upside: +16.38%
Oct 25, 2024
Maintains: Neutral
Price Target: $72 → $78
Current: $71.19
Upside: +9.57%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $69.43
Upside: +22.43%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $81.66
Upside: +10.21%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $38.88
Upside: +28.60%
Aug 7, 2024
Downgrades: Underweight
Price Target: n/a
Current: $5.84
Upside: -
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $8.37
Upside: -4.42%
May 1, 2024
Downgrades: Neutral
Price Target: $36 → $13
Current: $12.33
Upside: +5.43%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $269.62
Upside: -7.28%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $11.51
Upside: +39.01%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $7.14
Upside: -1.96%
Oct 17, 2023
Maintains: Overweight
Price Target: $340 → $181
Current: $160.94
Upside: +12.46%
May 24, 2023
Downgrades: Underweight
Price Target: $56 → $43
Current: $22.01
Upside: +95.37%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $14.97
Upside: +13.56%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $131.35
Upside: -10.16%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $106.11
Upside: +47.02%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $88.98
Upside: +18.00%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $103.62
Upside: -61.40%